News

The CD20 antibody is expected to have target specificity similar to Genetech’s Rituxan (rituximab) and to have relatively higher antibody dependent cell-mediated cytotoxicity. The existing relevant CD20 antibody

This multi-center open label Phase II safety and efficacy study is designed to enroll up to 40 glioblastoma patients who have experienced a first relapse. The study’s primary

In January 2007, Pozen and GSK responded to the FDA’s first approvable letter, submitting additional safety data from clinical trials, data from GSK’s database, and additional in vitro

The EC approval results in marketing authorization with unified labeling that will be valid in the 27 current EU member states as well as in Iceland and Norway.

In the primary endpoint analysis, Vidaza treatment was associated with a median survival of 24.4 months versus 15 months for those receiving conventional care regimens (CCR), an improvement

The National Institute for Clinical Excellence and Health, or NICE, said in the draft recommendation that Biogen Idec’s MabThera (rituximab) had very similar outcomes to Orencia (abatacept) at

The company said that while it regrets Bisaro’s decision to leave, it is confident that the departure will not have a negative effect on US or international operations

As a result of the reduction in workforce, effective August 3, 2007, the company expects to have less than 80 employees, a reduction of 45% from year end

Johnson & Johnson (J&J) has revealed initiatives that are expected to generate pre-tax, annual cost savings of between $1.3 and $1.6 billion for 2008, in an effort to